PHArmacotherapy Assessed Using Neuroprobing With TransOsseal Magnetic Stimulation

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06892457

Acronym

PHANTOMS

Enrollment

Registered

2025-03-24

Start date

2024-10-21

Completion date

2029-10-31

Last updated

2025-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Epilepsy

Keywords

Brain Excitability, Anti-Seizure Medication, Transcranial Magnetic Stimulation

Brief summary

The goal of this observational study is to investigate how prescribed anti-seizure medications (ASMs) affect cortical excitability in adults with epilepsy. The main questions it aims to answer are: 1. Does the magnitude of transcranial magnetic stimulation (TMS)-evoked potentials (TEPs) measured with electroencephalography (EEG) change between OFF and ON medication states? 2. Do these changes in TEP amplitude persist over time? Researchers will compare each participant's measurements in the OFF state with those in the ON state to see if TEPs change following ASM (re)start. Participants will undergo one TMS-EEG session scheduled around their prescribed ASM (re)start and one 1-6 months later.

Interventions

OTHERTMS-EEG

Evoked brain activity is measured with the help of TMS-EEG in epilepsy patients OFF and ON medication.

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Adult patients (≥ 18j) with epilepsy receiving a prescription for an anti-seizure medication for clinical reasons * Written informed consent

Exclusion criteria

* Presence of any electrical implants (e.g. neurostimulator or drug delivery system) or any metallic implants anywhere in the head (excluding teeth) * Increased intracranial pressure * Uncontrolled psychiatric disorder * Use of any kind of drug or alcohol, nicotine allowed * For female participants: If pregnancy cannot be ruled out with sufficient certainty, a pregnancy test (urine) will be carried out before using TMS * Inability to give consent

Design outcomes

Primary

Measure	Time frame	Description
Change in TEP magnitude	1 day	Whether the magnitude of measured TMS-evoked potentials (TEPs), measured as the line-length, is reduced between the OFF and ON ASM conditions.

Secondary

Measure	Time frame	Description
Persistence of TEP changes over time.	1-6 months	Number of participants with persistence of TEP changes over time.

Countries

Switzerland

Contacts

Primary ContactCecilia Friedrichs-Maeder, MD, MSc.

cecilia.friedrichs-maeder@insel.ch+41 79 394 44 63

Backup ContactMaxime Baud, MD-Phd

maxime.baud.neuro@gmail.com+41 79 385 96 90

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026